文献速递放疗物理与技术姑息放疗与转移瘤胸部肿瘤放疗

不确定潜能克隆性造血与放射治疗的关系

Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-10-24

该队列研究纳入489例接受过放疗的癌症患者,并与854例未接受放化疗的癌症患者对照,通过靶向DNA测序检测CHIP相关基因突变。结果显示放疗组CHIP检出率为23%,校正混杂因素后放疗与CHIP风险升高相关(OR 1.49,95%CI 1.08-2.05),且风险与生物等效剂量正相关,立体定向技术和脊柱照射也与CHIP相关。

要点

  • 放疗后CHIP检出率为23%,放疗与CHIP风险升高独立相关(OR 1.49)。
  • CHIP风险与生物等效剂量正相关(r=0.64,P<.001)。
  • 立体定向技术(OR 2.56)和脊柱照射者CHIP更常见。

核心结论

  • 既往放疗与克隆性造血风险升高相关,尤其在较高生物等效剂量、立体定向技术或脊柱照射的患者中。

研究设计与样本

  • 队列研究纳入489例接受放疗至少6个月后采血的癌症患者,排除既往血液恶性肿瘤或细胞毒性化疗暴露者,并与854例未接受放化疗的癌症患者对照。
  • 对血样本进行靶向DNA测序检测CHIP相关基因突变,并分析放疗剂量、技术和照射部位与CHIP患病率的关联。

主要发现

  • 放疗组CHIP检出率为23%,校正年龄、性别、种族、吸烟状态和转移性疾病状态后,放疗与CHIP风险升高相关(OR 1.49;95%CI 1.08-2.05)。
  • CHIP风险与生物等效剂量正相关(Pearson相关系数r=0.64,P<.001)。
  • CHIP与立体定向技术相关(OR 2.56;95%CI 1.01-6.34),且在原发性肺癌患者和接受脊柱照射的患者中更常见。
  • 放疗队列中观察到5例后续骨髓增生异常综合征和1例后续急性髓系白血病,放疗至诊断的中位间隔为6.3年;对照队列中观察到1例骨髓增生异常综合征,在采血后7.5年。

临床怎么用

  • 对接受高生物等效剂量、立体定向放疗或脊柱照射的患者,可关注CHIP相关风险并考虑长期血液学监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clonal hematopoiesis of indeterminate potential (CHIP) is a condition associated with increased risk of hematologic malignancies and cardiovascular diseases. Although radiation therapy has been identified as a risk factor for CHIP, specific radiation factors that influence the development of CHIP remain unclear. METHODS AND MATERIALS: We identified 489 patients with cancer who underwent radiation therapy (RT) at least 6 months prior to blood samples being deposited in an institutional biorepository. Patients with prior hematologic malignancy diagnosis or cytotoxic chemotherapy exposure were excluded. Targeted DNA sequencing of the blood samples was performed to detect mutations in CHIP-associated genes. CHIP prevalence was compared with a control cohort of 854 cancer patients without exposure to RT or chemotherapy. RT parameters, including dose, technique, and irradiated site, were characterized and examined for association with CHIP prevalence. RESULTS: CHIP was detected in 23% of patients who received RT. The probability of CHIP was increased in patients who received RT compared with the patients who did not (odds ratio, 1.49; 95% confidence interval, 1.08-2.05), after adjusting for age, sex, race, smoking status, and metastatic disease status. The risk of CHIP positively correlated with the biologically equivalent dose (Pearson correlation coefficient, r = 0.64, P < .001). CHIP was associated with the stereotactic technique (OR, 2.56; 95% CI, 1.01-6.34) and was more prevalent in patients with primary lung cancer and patients who received radiation to the spine. We observed 5 cases of subsequent myelodysplastic syndrome and 1 case of subsequent acute myeloid leukemia in the RT cohort with a median interval of 6.3 years between RT and diagnosis, and 1 case of myelodysplastic syndrome in the control cohort, 7.5 years after blood sample collection. CONCLUSIONS: In this cohort study, prior RT was associated with an increased risk of clonal hematopoiesis, particularly among patients receiving higher biologically equivalent radiation doses, stereotactic techniques, or treatment to the spine.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Crants SA, Olson SS, Li Y, et al. Clonal Hematopoiesis of Indeterminate Potential After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025. PMID: 41138783. doi:10.1016/j.ijrobp.2025.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。